The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Issue 2 (1st February 2017)

• Record Type: Journal Article
• Authors: Korycka-Wołowiec, Anna; Wołowiec, Dariusz; Robak, Tadeusz
• Is Part Of: Expert opinion on drug safety. Volume 16:Issue 2(2017:Feb.)
• Page Start: 185
• Page End: 201
• Publication Date: 2017-02-01
• Subjects: Chronic lymphocytic leukemia -- monoclonal antibodies -- safety profile -- biological treatment; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2017.1264387
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Monoclonal antibodies (MoAbs), non-chemotherapeutic agents targeting the antigens present on chronic lymphocytic leukemia (CLL) lymphocytes, are being implemented increasingly more often as treatment options. Areas covered : This article reviews the similarities and differences in the structure, mechanism of action, efficacy and safety profile of commercially-available MoAbs and prevents new agents potentially useful for CLL treatment. Publications in English before June 2016 were surveyed on the MEDLINE database for articles. Proceedings of the American Society of Hematology held during the last five years were also included. Expert opinion : MoAbs, especially those targeting CD20, are highly effective biological options for first-line and salvage treatment of CLL, particularly in chemoimmunotherapy, and possibly also as maintenance therapy. Treatment with MoAbs is associated with reduced risk of such adverse events as cytopenias, infections and secondary neoplasias and is generally well tolerated. Depending on antibody type, the most common adverse events are usually transient and limited to grade 1 and 2 infusion-related reactions. In addition to commercially available MoAbs, several other antibodies exist which are targeted against different antigens studied in the clinical trials.